Skip to main content

OraSure Technologies, Inc. (OSUR)

NASDAQ: OSUR · IEX Real-Time Price · USD
13.35
-0.03 (-0.22%)
After-hours:Sep 17, 2021 7:54 PM EDT
13.38
1.91 (16.65%)
At close: Sep 17, 4:00 PM
Market Cap939.72M
Revenue (ttm)227.06M
Net Income (ttm)5.31M
Shares Out71.98M
EPS (ttm)0.07
PE Ratio191.14
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,281,269
Open11.50
Previous Close11.47
Day's Range11.48 - 13.38
52-Week Range8.58 - 17.79
Beta-0.28
AnalystsBuy
Price Target13.25 (-1.0%)
Est. Earnings DateNov 3, 2021

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test...

IndustryHealth Care Equipment & Supplies
IPO DateNov 12, 1986
CEODouglas Michels
Employees570
Stock ExchangeNASDAQ
Ticker SymbolOSUR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 13.25, which is a decrease of -0.97% from the latest price.

Price Target
$13.25
(-0.97% downside)
Analyst Consensus: Buy

News

OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan

Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO

2 weeks ago - GlobeNewsWire

OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates

OraSure Technologies Inc (NASDAQ: OSUR) reported second-quarter revenues almost doubled to $57.6 million, slightly ahead of the consensus of $56.69 million. Excluding COVID-19 revenues, sales were up 12...

1 month ago - Benzinga

OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of -150.00% and 1.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

OraSure Technologies: Q2 Earnings Insights

Shares of OraSure Technologies (NASDAQ:OSUR) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 87.50% over the past year to ($0.02), whic...

1 month ago - Benzinga

OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business

Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

1 month ago - GlobeNewsWire

OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

OraSure Technologies, Inc. to Hold 2021 Second Quarter Earnings Conference Call Tuesday, August 3, 2021, 5:00 p.m. ET

BETHLEHEM, Pa., July 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain ...

1 month ago - GlobeNewsWire

OraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference

BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...

3 months ago - GlobeNewsWire

OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing

Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status

3 months ago - GlobeNewsWire

OraSure's COVID-19 Rapid Antigen Tests Gets FDA Emergency Approval for OTC, Professional, Prescription Use

OraSure Technologies Inc (NASDAQ: OSUR) has received FDA Emergency Use Authorization (EUA) for its COVID-19 rapid antigen tests, InteliSwab. These tests detect active COVID-19 infection; the agency has ...

3 months ago - Benzinga

OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescri...

Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection

3 months ago - GlobeNewsWire

OraSure Technologies to Present at the Jefferies Virtual Healthcare Conference

BETHLEHEM, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical ...

3 months ago - GlobeNewsWire

OraSure Resubmits EUA Applications for ELISA COVID-19 Antibody Test

OraSure Technologies Inc (NASDAQ: OSUR) has resubmitted two separate Emergency Use Authorization (EUA) applications for its SARS-CoV-2 Antibody ELISA and the oral specimen collection device. ELISA is in...

3 months ago - Benzinga

OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 18, 2021

BETHLEHEM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a li...

4 months ago - GlobeNewsWire

Insignia and Partners Support CDC Demonstration Project for Uptake of Self-test Kits for HIV

Free At-Home HIV Testing Kits Free At-Home HIV Testing Kits

4 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Beats Q1 Earnings and Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 66.67% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update

First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing

4 months ago - GlobeNewsWire

OraSure Technologies to Hold 2021 First Quarter Earnings Conference Call Wednesday, May 5, 2021, 5:00 p.m. ET

BETHLEHEM, Pa., April 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 first quarter financial results and certain ...

4 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q1 Release

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

OraSure Files Emergency Use Application For COVID-19 Kits For Home Use And Professional Test

OraSure Technologies Inc (NASDAQ: OSUR) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for its COVID-19 rapid antigen test for both Prescription Home Use and Professio...

5 months ago - Benzinga

OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emer...

Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow

5 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Q4 Earnings Miss Estimates

OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update

Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing

6 months ago - GlobeNewsWire

OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...

6 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Reports Next Week: Wall Street Expects Earnings Growth

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research